Market Overview

UPDATE: Credit Suisse Downgrades Johnson & Johnson to Underperform on Valuation

Share:
Related JNJ
Facebook, Google Make Glassdoor's List Of Top 50 Places To Work
Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia
Is Rebalancing A Stock Portfolio A Form Of Value Investing? (Seeking Alpha)

Credit Suisse downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Underperform and raised the price target from $71.00 to $73.00.

Credit Suisse commented, "Concurrent with Credit Suisse rating methodology requiring that ratings now reflect an expectation of relative out/(under) performance versus an analyst's coverage universe, we downgrade JNJ to Underperform from Neutral. While we advocate overweight positions in pharma stocks and acknowledge the stock's "index importance", JNJ offers the lowest total return in our coverage universe (dividend plus equity), hence this change. Along with adjustments to target price to other stocks in our sector, we raise JNJ's target to $73 from $71, below its current level of $75."

Johnson & Johnson closed at $75.39 on Wednesday.

Latest Ratings for JNJ

DateFirmActionFromTo
Nov 2016BarclaysDowngradesOverweightEqual-Weight
Sep 2016JefferiesMaintainsHold
Aug 2016JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!